The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Diverse Roles of TGF-β/Smads in Renal Fibrosis and Inflammation
Open accessAbstract
TGF-β1 has been long considered as a key mediator in renal fibrosis and induces renal scarring largely by activating its downstream Smad signaling pathway. Interestingly, while mice overexpressing active TGF-β1 develop progressive renal injury, latent TGF-β1 plays a protective role in renal fibrosis and inflammation. Under disease conditions, Smad2 and Smad3 are highly activated, while Smad7 is degraded through the ubiquitin proteasome degradation mechanism. In addition to TGF-β1, many pathogenic mediators such as angiotensin II and advanced glycation end products can also activate the Smad pathway via both TGF-β-dependent and independent mechanisms. Smads interact with other signaling pathways, such as the MAPK and NF-κB pathways, to positively or negatively regulate renal inflammation and fibrosis. Studies from gene knockout mice demonstrate that TGF-β1 acts by stimulating its downstream Smads to diversely regulate kidney injury. In the context of renal fibrosis and inflammation, Smad3 is pathogenic, while Smad2 and Smad7 are protective. Smad4 exerts its diverse roles by transcriptionally enhancing Smad3-mediated renal fibrosis while inhibiting NF-κB-driven renal inflammation via a Smad7-dependent mechanism. Furthermore, we also demonstrated that TGF-β1 acts by stimulating Smad3 to positively or negatively regulate microRNAs to exert its fibrotic role in kidney disease. In conclusion, TGF-β/Smad signaling is a major pathway leading to kidney disease. Smad3 is a key mediator in renal fibrosis and inflammation, whereas Smad2 and Smad7 are renoprotective. Smad4 exerts its diverse role in promoting renal fibrosis while inhibiting inflammation. Thus, targeting the downstream TGF-β/Smad3 signaling pathway by gene transfer of either Smad7 or Smad3-dependent microRNAs may represent a specific and effective therapeutic strategy for kidney disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
REGULATION OF IMMUNE RESPONSES BY TGF-β
Letterio, J. J., & Roberts, A. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.137 · Cited by 1,890
Dennler, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3091 · Cited by 1,793
Zeisberg, M., Hanai, J.-I., Sugimoto, H., Mammoto, T., Charytan, D., Strutz, F., & Kalluri, R. (2003) · Nature Medicine · doi:10.1038/nm888 · Cited by 1,346
Smad7 Binds to Smurf2 to Form an E3 Ubiquitin Ligase that Targets the TGFβ Receptor for Degradation
Kavsak, P., Rasmussen, R. K., Causing, C. G., Bonni, S., Zhu, H., Thomsen, G. H., & Wrana, J. L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00134-9 · Cited by 1,205
Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways
Lagna, G., Hata, A., Hemmati-Brivanlou, A., & Massagué, J. (1996) · Nature · doi:10.1038/383832a0 · Cited by 905
Ebisawa, T., Fukuchi, M., Murakami, G., Chiba, T., Tanaka, K., Imamura, T., & Miyazono, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100008200 · Cited by 844
Sato, M., Muragaki, Y., Saika, S., Roberts, A. B., & Ooshima, A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19270 · Cited by 831
Li, M. O., Sanjabi, S., & Flavell, R. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.011 · Cited by 805
Li, M. O., Wan, Y. Y., & Flavell, R. A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.014 · Cited by 733
Cited by
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
New insights into TGF-β/Smad signaling in tissue fibrosis
Hu, H.-H., Chen, D.-Q., Wang, Y.-N., Feng, Y.-L., Cao, G., Vaziri, N. D., & Zhao, Y.-Y. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.07.008 · Cited by 1,179
TGF-β signalling and its role in cancer progression and metastasis
Drabsch, Y., & ten Dijke, P. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9375-7 · Cited by 428
Diabetic nephropathy and inflammation
Duran-Salgado, M. B. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.393 · Cited by 382
Antar, S. A., Ashour, N. A., Marawan, M. E., & Al-Karmalawy, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044004 · Cited by 366
Chen, L., Yang, T., Lu, D.-W., Zhao, H., Feng, Y.-L., Chen, H., Chen, D.-Q., Vaziri, N. D., & Zhao, Y.-Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.090 · Cited by 359
miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes
Zhong, X., Chung, A. C. K., Chen, H. Y., Dong, Y., Meng, X. M., Li, R., Yang, W., Hou, F. F., & Lan, H. Y. (2013) · Diabetologia · doi:10.1007/s00125-012-2804-x · Cited by 355
Self-citationRole of the TGF-β/BMP-7/Smad pathways in renal diseases
Meng, X.-M., Chung, A. C. K., & Lan, H. Y. (2013) · Clinical Science · doi:10.1042/cs20120252 · Cited by 354
Self-citationWick, G., Grundtman, C., Mayerl, C., Wimpissinger, T.-F., Feichtinger, J., Zelger, B., Sgonc, R., & Wolfram, D. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095937 · Cited by 327
Renal interstitial fibrosis: mechanisms and evaluation
Farris, A. B., & Colvin, R. B. (2012) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e3283521cfa · Cited by 298
TGF-β 1/Smads and miR-21 in Renal Fibrosis and Inflammation
Loboda, A., Sobczak, M., Jozkowicz, A., & Dulak, J. (2016) · Mediators of Inflammation · doi:10.1155/2016/8319283 · Cited by 297
Vitamin D in inflammatory diseases
Wöbke, T. K., Sorg, B. L., & Steinhilber, D. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00244 · Cited by 284
Diverse Role of TGF-β in Kidney Disease
Gu, Y.-Y., Liu, X.-S., Huang, X.-R., Yu, X.-Q., & Lan, H.-Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00123 · Cited by 257
Self-citationEmerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks
Śmiech, M., Leszczyński, P., Kono, H., Wardell, C., & Taniguchi, H. (2020) · Genes · doi:10.3390/genes11111342 · Cited by 168
TGF-β as A Master Regulator of Aging-Associated Tissue Fibrosis
Ren, L.-L., Miao, H., Wang, Y.-N., Liu, F., Li, P., & Zhao, Y.-Y. (2023) · Aging and disease · doi:10.14336/ad.2023.0222 · Cited by 139
Yiu, W. H., Wong, D. W. L., Chan, L. Y. Y., Leung, J. C. K., Chan, K. W., Lan, H. Y., Lai, K. N., & Tang, S. C. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088894 · Cited by 50
Self-citationYang, X., Wang, H., Tu, Y., Li, Y., Zou, Y., Li, G., Wang, L., & Zhong, X. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29187 · Cited by 42
Regulation of Renal Fibrosis by Smad3 Thr388 Phosphorylation
Qu, X., Li, X., Zheng, Y., Ren, Y., Puelles, V. G., Caruana, G., Nikolic-Paterson, D. J., & Li, J. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.12.003 · Cited by 33
Vesicoureteral reflux and the extracellular matrix connection
Tokhmafshan, F., Brophy, P. D., Gbadegesin, R. A., & Gupta, I. R. (2017) · Pediatric Nephrology · doi:10.1007/s00467-016-3386-5 · Cited by 30
Miao, Y., Wang, M., Cai, X., Zhu, Q., & Mao, L. (2022) · Bioengineered · doi:10.1080/21655979.2022.2048775 · Cited by 22
Asiaticoside inhibits renal fibrosis development by regulating the miR‐142‐5p/ACTN4 axis
Zhang, M., Liu, S., Fang, L., Wang, G., & Yin, L. (2022) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2110 · Cited by 7
Retracted
Metadata
- Authors
- Lan, H. Y.
- Venue
- International Journal of Biological Sciences
- Publisher
- Ivyspring International Publisher
- Published
- 2011
- Volume
- 7
- Issue
- 7
- Pages
- 1056-1067
- ISSN
- 1449-2288 (ISSN-L)
- OpenAlex
- W2104274897
- Cited by
- 652
- References
- 75
- FWCI
- 12.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.